Merck announced that new data from its HIV prevention and treatment pipeline will be presented at the 13th International AIDS Society Conference on HIV Science (IAS 2025), taking place July 13-17, 2025, in Kigali, Rwanda.

Merck will share data from its HIV clinical programs, including Phase 2 results on the safety and pharmacokinetics of MK-8527, an investigational oral, once-monthly nucleoside reverse transcriptase translocation inhibitor (NRTTI) being developed for HIV prevention as pre-exposure prophylaxis (PrEP).

HIV clinical data from three Phase 3 trials will examine the impact of preexisting resistance-associated mutations (RAMs) in proviral DNA on virologic response to doravirine/islatravir (DOR/ISL), focusing on M184I/V in proviral DNA.

Additional data will be presented on a once-weekly oral combination of islatravir and ulonivirine (ISL/ULO) for HIV-1 treatment. Results include two Phase 1 trials evaluating safety and drug interactions in adults without HIV, and a Phase 2b dose-ranging study using a higher (20 mg) dose of islatravir and three doses of ulonivirine in treatment-naive adults with HIV-1. Based on trial results and pharmacokinetic modeling, a once-weekly oral dose of islatravir (2 mg) and ulonivirine (200 mg) is progressing in development.

“As we continue our HIV research, we are pleased to present data across our HIV pipeline at IAS 2025, including new findings from our NRTTI programs,” said Dr. Elizabeth Rhee, vice president, global clinical development, Merck Research Laboratories. “With daily, weekly, and monthly oral regimens in development, we aim to provide options that meet the changing needs of people living with or at risk of HIV.”